Performance and Safety of Silicone Hydrogel Soft Contact Lenses
Primary Purpose
Myopia
Status
Unknown status
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
41% Silicone Hydrogel Soft Contact Lenses(SHSCL)
ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens
Contact Lens Care Product
Contact Lens Case
Sponsored by
About this trial
This is an interventional treatment trial for Myopia focused on measuring Nearsightedness, Eye wear, Myopia control, Contact lens
Eligibility Criteria
Inclusion Criteria:
A person is eligible for inclusion in the study if he/she:
- Healthy adult males or females age ≥20-45 years of age;
- Be a currently adapted soft contact lens wearer (i.e. be wearing lenses at least 1 month prior to enrolment) and the last contact lenses worn more than a week ago;
- Have a contact lens powers between -2.00D and -6.00D (both inclusive) in both eyes;
- Astigmatism of 1.00D or less in both eyes;
- Be able to wear the lens powers available for this study;
- Be correctable to a visual acuity of 0.8 decimal (+0.10 logMAR) or better in each eye;
- The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol;
- The subject must read and sign the Informed Consent form.
Exclusion Criteria:
A person will be excluded from the study if he/she:
- Previously unsuccessful with contact lens wear, worn rigid gas permeable contact lenses within past 12 months;
- Women who are pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
- Any ocular or systemic allergies or diseases that may contraindicate contact lens wear;
- Any ocular medications use within the last one month;
- Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear;
- Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report;
- Any current or previous orthokeratology treatment, or planned for orthokeratology treatment during the study;
- Any previous history of ocular and/or refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.), or planned for ocular and/or refractive surgery during the study
- History of herpetic keratitis;
- History of binocular vision abnormality or strabismus, by self-report;
- Allergic reactions to test lens, control lens or the contact lens solution used in this study;
- A clinical finding or history of entropion, ectropion, chalazia, recurrent styes, glaucoma, pathologically dry eye, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion, by self-report;
- Employee of investigational clinic (e.g., Investigator, Coordinator, Technician);
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment;
- Any slit lamp findings which would contraindicate contact lens wear;
- Any history of a contact lens-related corneal inflammatory event within the past 12 months that may contraindicate contact lens wear; or
- Clinically significant (grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures;
- Subjects are considered ineligible for the study as judged by the investigator.
Sites / Locations
- ApexLens Co., Ltd.Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
41% Silicone hydrogel Soft contact lenses (SHSCL)
ACUVUE® VITA™
Arm Description
Healthy adult males or females age ≥20-45 years of age
Healthy adult males or females age ≥20-45 years of age
Outcomes
Primary Outcome Measures
Best-corrected contact lens visual acuity
The primary efficacy endpoint in this evaluation is the percentage of subjects with best-corrected contact lens visual acuity of 0.8 decimal (+0.10 logMAR) and 1.0 decimal (0.00 logMAR) or better.
The Snellen chart will be used for visual acuity testing.
Permanent loss of visual acuity
The primary safety endpoint in this evaluation is the percentage of subjects with permanent loss of two or more lines of visual acuity.
Serious adverse reactions
The primary safety endpoint in this evaluation is the rate of serious adverse reactions related to visual acuity loss as well as accompanying slit-lamp findings and other associated observations.
Secondary Outcome Measures
Lens comfort
The secondary efficacy endpoint is the assessment of lens comfort over time with the lens for the recommended wearing time. This will be measured using Study Diary.
Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.
Comfort after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Symptoms of dryness
The secondary efficacy endpoint is the assessment of dryness symptoms with the lens for the recommended wearing time. This will be measured using Study Diary.
Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.
Dryness after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Slit lamp findings
The secondary efficacy endpoint is the assessment of the rate of any Slit Lamp Findings > Grade 2.
The subject will be instructed to take off the study lenses before the slit-lamp biomicroscopy assessment.
Slit-lamp biomicroscopy will be assessed according to the approved study biomicroscopy CRF.
ISO 11980:2012 Annex B will be used to grade the Slit-lamp findings.
Subject reported ocular complaints
Subjects will be asked to assess ocular complaints by using Study Diary.
Full Information
NCT ID
NCT04226560
First Posted
January 2, 2020
Last Updated
February 23, 2021
Sponsor
ApexLens Co., Ltd.
Collaborators
Chang Gung Memorial Hospital, Taipei Medical University WanFang Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04226560
Brief Title
Performance and Safety of Silicone Hydrogel Soft Contact Lenses
Official Title
Clinical Evaluation of the Clinical Performance and Safety of a New Monthly Disposable Silicone Hydrogel Soft Contact Lenses
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
April 20, 2020 (Actual)
Primary Completion Date
May 30, 2021 (Anticipated)
Study Completion Date
May 30, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ApexLens Co., Ltd.
Collaborators
Chang Gung Memorial Hospital, Taipei Medical University WanFang Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To demonstrate substantial equivalence of the new Silicone Hydrogel Soft Contact Lenses(SHSCL) to the commercially available ACUVUE® VITA™ contact lens
Detailed Description
This study is a prospective, subject-masked, bilateral, randomized, parallel group dispensing study comparing the SHSCL test lens against the 1-Month ACUVUE® VITA™ (1-MAV) control lenses. Each subject will be randomized to wear either the test or of the control with similar/comparable lens parameters optimized for vision.
Both test and control lens will be used in their daily wear, monthly replacement modality for thirteen (13) weeks. It is anticipated that this study will involve up to 6 scheduled visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia
Keywords
Nearsightedness, Eye wear, Myopia control, Contact lens
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
65 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
41% Silicone hydrogel Soft contact lenses (SHSCL)
Arm Type
Experimental
Arm Description
Healthy adult males or females age ≥20-45 years of age
Arm Title
ACUVUE® VITA™
Arm Type
Active Comparator
Arm Description
Healthy adult males or females age ≥20-45 years of age
Intervention Type
Device
Intervention Name(s)
41% Silicone Hydrogel Soft Contact Lenses(SHSCL)
Intervention Description
Silicone Hydrogel
Intervention Type
Device
Intervention Name(s)
ACUVUE® VITA™ (senofilcon C) Brand (Soft) Contact Lens
Intervention Description
Senofilcon C (USFDA Device License #K160212)
Intervention Type
Other
Intervention Name(s)
Contact Lens Care Product
Other Intervention Name(s)
Opti-Free Replenish Multi-purpose Disinfecting Solution
Intervention Description
Cefatrizine (propylene Glycol), Sodium Citrate (sodium Citrate Tribasic), Sodium Chloride, Sodium Borate (sodium Biboratesodium Tetraborate, Polyquaternium -1, Hydrochloric Acid, Sodium Hydroxide, Water Purified ( Eq to Aqueous Purified Or Purified Water ), Tetronic 1304, Myristamidopropyl Dimethylamine, Nonanoyl Ethylenediaminetriacetic Acid
Intervention Type
Other
Intervention Name(s)
Contact Lens Case
Other Intervention Name(s)
"Alcon" Soft (hydrophilic) Contact Lens Case (Non-Sterile)
Intervention Description
"Alcon" Soft (hydrophilic) Contact Lens Case (Non-Sterile)
Primary Outcome Measure Information:
Title
Best-corrected contact lens visual acuity
Description
The primary efficacy endpoint in this evaluation is the percentage of subjects with best-corrected contact lens visual acuity of 0.8 decimal (+0.10 logMAR) and 1.0 decimal (0.00 logMAR) or better.
The Snellen chart will be used for visual acuity testing.
Time Frame
13 weeks
Title
Permanent loss of visual acuity
Description
The primary safety endpoint in this evaluation is the percentage of subjects with permanent loss of two or more lines of visual acuity.
Time Frame
13 weeks
Title
Serious adverse reactions
Description
The primary safety endpoint in this evaluation is the rate of serious adverse reactions related to visual acuity loss as well as accompanying slit-lamp findings and other associated observations.
Time Frame
13 weeks
Secondary Outcome Measure Information:
Title
Lens comfort
Description
The secondary efficacy endpoint is the assessment of lens comfort over time with the lens for the recommended wearing time. This will be measured using Study Diary.
Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.
Comfort after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Time Frame
13 weeks
Title
Symptoms of dryness
Description
The secondary efficacy endpoint is the assessment of dryness symptoms with the lens for the recommended wearing time. This will be measured using Study Diary.
Subject will be given a Study Diary to be completed at home, to reflect their lens wear experience at the time of rating. Subject will be given careful explanation of how and when to complete them.
Dryness after insertion (i.e. after lens settling), after 4 hours, and just before lens removal (0-10 scale)(10 = cannot be felt, 0 = painful)
Time Frame
13 weeks
Title
Slit lamp findings
Description
The secondary efficacy endpoint is the assessment of the rate of any Slit Lamp Findings > Grade 2.
The subject will be instructed to take off the study lenses before the slit-lamp biomicroscopy assessment.
Slit-lamp biomicroscopy will be assessed according to the approved study biomicroscopy CRF.
ISO 11980:2012 Annex B will be used to grade the Slit-lamp findings.
Time Frame
13 weeks
Title
Subject reported ocular complaints
Description
Subjects will be asked to assess ocular complaints by using Study Diary.
Time Frame
13 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A person is eligible for inclusion in the study if he/she:
Healthy adult males or females age ≥20-45 years of age;
Be a currently adapted soft contact lens wearer (i.e. be wearing lenses at least 1 month prior to enrolment) and the last contact lenses worn more than a week ago;
Have a contact lens powers between -2.00D and -6.00D (both inclusive) in both eyes;
Astigmatism of 1.00D or less in both eyes;
Be able to wear the lens powers available for this study;
Be correctable to a visual acuity of 0.8 decimal (+0.10 logMAR) or better in each eye;
The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol;
The subject must read and sign the Informed Consent form.
Exclusion Criteria:
A person will be excluded from the study if he/she:
Previously unsuccessful with contact lens wear, worn rigid gas permeable contact lenses within past 12 months;
Women who are pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit);
Any ocular or systemic allergies or diseases that may contraindicate contact lens wear;
Any ocular medications use within the last one month;
Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear;
Any infectious disease (e.g., hepatitis, tuberculosis) or a contagious immunosuppressive disease (e.g., HIV), by self-report;
Any current or previous orthokeratology treatment, or planned for orthokeratology treatment during the study;
Any previous history of ocular and/or refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.), or planned for ocular and/or refractive surgery during the study
History of herpetic keratitis;
History of binocular vision abnormality or strabismus, by self-report;
Allergic reactions to test lens, control lens or the contact lens solution used in this study;
A clinical finding or history of entropion, ectropion, chalazia, recurrent styes, glaucoma, pathologically dry eye, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion, by self-report;
Employee of investigational clinic (e.g., Investigator, Coordinator, Technician);
Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment;
Any slit lamp findings which would contraindicate contact lens wear;
Any history of a contact lens-related corneal inflammatory event within the past 12 months that may contraindicate contact lens wear; or
Clinically significant (grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures;
Subjects are considered ineligible for the study as judged by the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rex Tsou
Phone
886-3-5752910
Ext
206
Email
rex.tsou@apexlens.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yih-Shiou Hwang, M.D.,Ph.D.
Organizational Affiliation
Chang Gung Memorial Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hsin-Wei Huang, M.D.
Organizational Affiliation
Taipei Medical University - Municipal Wan Fang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
ApexLens Co., Ltd.
City
Hsinchu
ZIP/Postal Code
300
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rex Tsou
Phone
886-3-5752910
Ext
206
Email
rex.tsou@apexlens.com
First Name & Middle Initial & Last Name & Degree
Yih-Shiou Hwang, M.D.,Ph.D.
First Name & Middle Initial & Last Name & Degree
Hsin-Wei Huang, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
21493121
Citation
Dumbleton KA, Woods CA, Jones LW, Fonn D. The relationship between compliance with lens replacement and contact lens-related problems in silicone hydrogel wearers. Cont Lens Anterior Eye. 2011 Oct;34(5):216-22. doi: 10.1016/j.clae.2011.03.001. Epub 2011 Apr 13.
Results Reference
result
Learn more about this trial
Performance and Safety of Silicone Hydrogel Soft Contact Lenses
We'll reach out to this number within 24 hrs